|Bid||116.00 x 1300|
|Ask||121.69 x 800|
|Day's Range||120.11 - 121.69|
|52 Week Range||96.18 - 149.34|
|PE Ratio (TTM)||61.46|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Since the start of 2018, Alexion Pharmaceuticals (ALXN) has fallen -2.5% to close at $121 as of May 16. Alexion Pharmaceuticals generated $300 million from operating activities in the first quarter of 2018 compared to $308 million in the first quarter of 2017. In the first quarter of 2018, Alexion Pharmaceuticals used $254.7 million in investing activities compared to $495.3 million in the first quarter of 2017.
Alexion Pharmaceuticals (ALXN) is conducting two Phase 3 clinical studies in patients suffering from aHUS (atypical hemolytic uremic syndrome), which leads to life-threatening damage to the kidney, brain, heart, and other critical organs. This plan entails a once-per-week dosing to PNH (paroxysmal nocturnal hemoglobinuria) patients to support registration in PNH as well as aHUS.
Alexion Pharmaceuticals (ALXN) generated total revenue of $931 million in the first quarter of 2018 compared to $870 million in the first quarter of 2017. The increase in its sales resulted from an increase in its unit volumes due to increased global demand for Soliris and increased sales of Strensiq and Kanuma due to Alexion’s efforts to increase its patient outreach.
Alexion Pharmaceuticals’ (ALXN) Kanuma is a recombinant form of the human LAL (lysosomal acid lipase) enzyme and is the only enzyme-replacement therapy approved by the FDA for the treatment of patients suffering from LAL deficiency (or LAL-D).
Alexion Pharmaceuticals’ (ALXN) major products include Soliris, Strensiq, and Kanuma. Soliris is a humanized monoclonal antibody targeted at treating inflammation associated with chronic disorders in several therapeutic areas, including hematology, nephrology, and neurology. Soliris has received approval for the treatment of PNH in the United States, Europe, Japan, and several other countries.
Here we used TipRanks' stock screener to pinpoint the most compelling stocks right now. The Street is buzzing about Neurocrine's Ingrezza drug, the first FDA-approved treatment for adults with tardive dyskinesia. On its first quarter earnings call, Neurocrine updated the Street with respect to ongoing market penetration for Ingrezza.
In May, Jazz Pharmaceuticals (JAZZ) submitted a supplemental new drug application (or sNDA) to the FDA for the label expansion of Xyrem for the inclusion of its use in the treatment of cataplexy and EDS (excessive daytime sleepiness) in pediatric patients with narcolepsy. In April, Jazz Pharmaceuticals entered into an agreement with Spark Therapeutics (ONCE) whereby Jazz would purchase a rare pediatric disease priority review voucher for $110 million that would allow it to accelerate the FDA review process for one of its future regulatory submissions. Of the 23 analysts tracking Jazz Pharmaceuticals in May, six have recommended “strong buys” on the stock, while 13 have recommended “buys.” Four analysts have recommended “holds” on Jazz Pharmaceuticals in May.
In 1Q18, Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million compared to $376.1 million in 1Q17, which reflected an ~18% rise on a YoY (year-over-year) basis and a ~2% rise quarter-over-quarter.
Only 10 states nationwide grew their gross domestic product more quickly than Massachusetts did last year.
Conventional wisdom says that insiders and 10-percent owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. A director of DDR Corp (NYSE: DDR) has been buying shares of this shopping center-focused real estate investment trust since February, including this past week's more than 1.9 million shares. Note that the latest purchases brought his stake to more than 55.47 million shares out of about 340 million shares outstanding.
The biotech sector was in focus over the last five trading sessions as several bigwigs like Gilead and Vertex, among others reported results while some others provided pipeline updates.
In February 2018, Vertex Pharmaceuticals (VRTX) announced the results of a Phase 2 trial for VX-150, an investigational NaV1.8 inhibitor. It had positive results in patients with acute pain after bunion removal and was well tolerated by patients.
In 1Q18, Vertex Pharmaceuticals’ (VRTX) revenue rose ~33% YoY (year-over-year) to $638 million from $481 million. It grew ~3% quarter-over-quarter.
Alexion (ALXN) was a big mover last session, as the company saw its shares rise more than 14% on the day amid huge volumes.
In 1Q18, Alexion Pharmaceuticals (ALXN) generated revenues of $930.9 million compared to $870 million in 1Q17, a ~7% increase on a year-over-year (or YoY) basis and a ~2% increase on a quarter-over-quarter basis. In the US, Europe, and Asia-Pacific, Alexion Pharmaceuticals generated revenues of $437.1 million, $270.7 million, and $92.2 million, respectively, compared to $360.1 million, $248.3 million, and $83.0 million in 1Q17.
Alexion Pharmaceuticals reported adjusted profit of $1.68 per share and $930.9 million in sales for its first quarter.
When the company moves into its new headquarters in the Seaport District this summer, it will become the state’s third most valuable drugmaker.
Alexion exceeds both earnings and sales expectations in the first quarter of 2018.The company also raised revenue and earnings guidance for 2018.
With earnings season in full swing, pharma stocks got a boost today from AbbVie (ABBV), and Alexion Pharmaceuticals (ALXN), although Bristol-Myers Squibb (BMY) has given up its early gains. AbbVie said ...